![Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 | Nature Medicine Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01590-5/MediaObjects/41591_2021_1590_Fig1_HTML.png)
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 | Nature Medicine
![AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1584625962/CoronaBugOnline.jpg/CoronaBugOnline.jpg?VersionId=Z.M57RATA4iD7w1WZ614GWU5d7.cYc76)
AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma
PLOS Medicine: Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
![Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers | JCO Global Oncology Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/go/2020/go.2020.6/go.20.00153/20200728/images/large/go.20.00153t2.jpeg)
Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers | JCO Global Oncology
![Strengthening capacity for AIDS vaccine research: analysis of the Pfizer Global Health Fellows Program and the International AIDS Vaccine Initiative | BMC Health Services Research | Full Text Strengthening capacity for AIDS vaccine research: analysis of the Pfizer Global Health Fellows Program and the International AIDS Vaccine Initiative | BMC Health Services Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1472-6963-13-378/MediaObjects/12913_2012_Article_2823_Fig1_HTML.jpg)
Strengthening capacity for AIDS vaccine research: analysis of the Pfizer Global Health Fellows Program and the International AIDS Vaccine Initiative | BMC Health Services Research | Full Text
![Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda | Article | NursingCenter Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda | Article | NursingCenter](https://www.nursingcenter.com/wkhlrp/handlers/Cv.png?key=cv_00001782-201910000-00000)
Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda | Article | NursingCenter
![Journal of Immunological Methods | Building Global Resource Programs to Support HIV/AIDS Clinical Trial Studies | ScienceDirect.com by Elsevier Journal of Immunological Methods | Building Global Resource Programs to Support HIV/AIDS Clinical Trial Studies | ScienceDirect.com by Elsevier](https://ars.els-cdn.com/content/image/1-s2.0-S0022175914X00098-cov200h.gif)
Journal of Immunological Methods | Building Global Resource Programs to Support HIV/AIDS Clinical Trial Studies | ScienceDirect.com by Elsevier
![A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls - eBioMedicine A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/06e4c98b-0783-4062-908f-52e0832f391d/gr1.jpg)
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls - eBioMedicine
![Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial - The Lancet HIV Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial - The Lancet HIV](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/58690bd2-3e4a-401f-8bb0-1d24f8f4ddf8/gr1a_lrg.jpg)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial - The Lancet HIV
![Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies . Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies .](https://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/14680/PMID24910413.pdf.jpg?sequence=4&isAllowed=y)